
COVID-19 Abdala Vaccine Development Timeline

2020

- **March** Constitution of the research group for the development of the anti-COVID-19 vaccine project
- **May 19** Presentation of the development strategies of vaccine candidates to President Miguel Díaz-Canel Bermúdez
- **September 8** Obtaining the recombinant clone that produces the protein binding domain (RBD) of the SARS-CoV-2 virus spike to its receptor and expression in the yeast *Pichia pastoris*
- **October 23 - November 17** Production of the first batches of the vaccine candidate CIGB 66
- **December 3** Delivery of the clinical study request to the Center for State Control of Medicines and Medical Devices (Cecmed)
- **December 7** Start of the phase I-II clinical study in people over 19 years of age to demonstrate the safety and immunogenicity of the vaccine candidate.

2021

- **January 22** First immunogenicity results of the short scheme in the phase I clinical study
- **March 19** Scaling up the production of the recombinant RBD protein
- **March 22** Start of the phase III clinical trial in the provinces of Granma, Santiago de Cuba and Guantánamo
- **March 29** Start of the study of Intervention in risk personnel of the Minsap and Biocubafarma
- **May 9** Sanitary Intervention begins in four municipalities of Havana and other provinces

- **June 21** Announcement of the effectiveness of 92.28% against symptomatic disease.
- **June 18** Approval of the Emergency Use Authorization (AUE) in the Bolivarian Republic of Venezuela.
- **July 9** Approval of the AUE in Cuba by Cecmed
- **July 15** The Ismaelillo phase I-II clinical study begins in pediatric population between 3 and 18 years of age in Camagüey
- **July 16** The result of the phase III clinical study is reported: 100% efficacy in preventing severe systemic disease and death
- **July 18** Start of the phase I-II clinical study in convalescent adults from COVID-19 with the vaccine candidate Mambisa and the Abdala vaccine
- **July 29** Vaccination of pregnant and lactating mothers begins
- **September 15** Immunization begins for the pediatric population between 17 and 18 years of age
- **September 15** Delivery of 20 million doses to the Cuban public health system
- **September 17** Announcement of the 90% effectiveness of the vaccine in the presence of the Delta variant of the SARS-CoV-2 virus in Havana
- **September 18** Vietnam approved the AUE
- **September 20** Signing of the export agreement for 5 million doses to Vietnam
- **September 24** Export of 1,050,000 doses to Vietnam
- **September 25** Export of 150,000 doses to Venezuela
- **October 1** Approval of the Emergency Use Authorization in Nicaragua